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Abstract
Falciparum malaria is an important cause of maternal, perinatal and neonatal morbidity in high
transmission settings in Sub-Saharan Africa. Intermittent preventive treatment with sulphadoxine-
pyrimethamine (SP-IPT) has proven efficacious in reducing the burden of pregnancy-associated
malaria but increasing levels of parasite resistance mean that the benefits of national SP-IPT
programmes may soon be seriously undermined in much of the region. Hence, there is an urgent
need to develop alternative drug regimens for IPT in pregnancy. This paper reviews published safety
and efficacy data on various antimalarials and proposes several candidate combination regimens for
assessment in phase II/III clinical trials.
Background
Falciparum malaria is an important cause of maternal
anaemia, intra-uterine growth retardation, intrauterine
death, stillbirth, premature delivery, low birth weight
(LBW), perinatal and neonatal morbidity and mortality
[1-5] and postpartum morbidity [6-8]. In sub-Saharan
Africa, poor nutrition, micronutrient imbalances (particu-
larly vitamin A, zinc, iron and folate)[1], HIV co-infection
[9-12], poverty and limited access to effective primary
health care and emergency obstetric services [13-15] exac-
erbate the impact of pregnancy-associated malaria.
In areas of high or moderate transmission, most malaria
infections in pregnant women are asymptomatic and
infected women do not present for treatment. In such
areas, the World Health Organization recommends a
combination of interventions to prevent malaria in preg-
nancy including insecticide-treated bednets (ITNs), inter-
mittent preventive treatment in pregnancy (IPTp) and
effective case management and treatment[16,17]. A small
number of randomized controlled trials and prospective
studies conducted in Kenya[18,19] and Malawi[20,21] in
the 1990s demonstrated the efficacy, safety and cost-effec-
tiveness[22] of sulphadoxine-pyrimethamine (SP) IPTp in
preventing maternal anaemia and LBW. The results of
these studies led to a recommendation by the World
Health Organization that, in areas of medium or high
malaria transmission, IPTp with SP should be given on at
least two occasions following quickening[17]. Many
countries in sub-Saharan Africa have subsequently intro-
duced SP-IPTp into national malaria control programmes
[23-25], but levels of coverage are still only modest in
most. Although strenuous efforts are being made to
increase coverage levels with SP IPTp, its effectiveness is
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being threatened by increasing levels of resistance to SP
across Africa[23,26-32] and in SE Asia[33,34]. Thus, some
authors have suggested that SP should be combined with
artemisinins or with cheaper and more readily available
alternatives, such as chloroquine or amodiaquine[35] to
maintain the effectiveness of SP-IPTp or that other drug
regimens should be used[36]. Several antimalarials, nota-
bly chloroquine, proguanil, mefloquine and proguanil-
atovaquone, have been evaluated for malaria chemo-
prophylaxis in pregnancy[4,37-43], but few clinical trials
have attempted to evaluate alternatives to SP in IPTp regi-
mens. Three IPTp clinical trials are currently underway in
Benin, Malawi and Tanzania [44-46] and will evaluate SP
vs mefloquine[44]; SP alone vs SP plus artesunate[45]; and
SP alone vs SP plus azithromycin[46] respectively. A phase
III clinical trial among 900 pregnant women in Ghana
concluded that amodiaquine alone or in combination
with SP was effective in treating uncomplicated falci-
parum malaria[47], but concerns about the safety and tol-
erability of amodiaquine in pregnancy[48,49] and
widespread resistance, particularly in East Africa[23], are
likely to hinder development of amodiaquine-containing
combinations for IPTp.
The future of SP for intermittent preventive treatment of
malaria in pregnancy is tenuous, particularly in East and
Southern Africa, and there are insufficient, reliable data
on the safety and efficacy of alternative antimalarials for
the prevention and treatment of malaria in preg-
nancy[50]. Hence, there is an urgent need to evaluate new
drug combinations, particularly in areas where multi-drug
resistant falciparum malaria is common[17]. This paper
summarizes the current literature on this topic and sug-
gests which antimalarial combinations should be consid-
ered for future phase II/III clinical trials among pregnant
women in Africa. Key factors reviewed include evidence of
safety, acceptability and favourable pharmacokinetic pro-
file in pregnancy; the feasibility of producing fixed-dose
co-formulations at costs affordable to most malaria-
endemic countries; and the possibility of simple dosing
regimens [51-54]. The value of combining drugs with dif-
fering molecular targets, those likely to show synergy in
combination and those having comparable or disparate
elimination half-lives are also discussed[55].
Methods
Search strategy
A two-stage, systematic search was carried out in PubMed
and EMBASE using combinations of the keywords: preg-
nancy, malaria, antenatal, prophylaxis, intermittent, pre-
vention, clinical trial. Alternative spellings and truncated
forms were also used[56]. Articles published between
1985 and 2006 were included. Relevant references cited in
review articles were also obtained. Full text articles were
accessed through the WHO HINARI system designed for
research institutions in developing counties[57]. Follow-
ing a review of the initial search results, several antimalar-
ial drugs were excluded from further review due to their
established toxicity during pregnancy (e.g. tetracycline,
doxycycline), theoretical contra-indications (e.g. pri-
maquine, halofantrine)[54,58] or widespread resistance
in the region (chloroquine, amodiaquine)[23]. The fol-
lowing drugs were included in a second literature search
(conducted in combination with the keywords above):
mefloquine; azithromycin; proguanil; chlorproguanil;
dapsone; atovaquone; artesunate; artemether; dihydroar-
temisinin; lumefantrine; piperaquine. Trade names (e.g.
Artekin©, Malorone©, Coartem©, Lapdap©, truncated forms
and associated terms (e.g. macrolide, artemisinin, arte*)
were used where it was felt appropriate. Manufacturers'
information sheets, guidelines and reports from the
World Health Organization (WHO), Medicines for
Malaria Venture (MMV), Gates Malaria Partnership
(GMP) and other leading organizations in the field were
also scrutinized.
Results
Mefloquine
Mefloquine hydrochloride is a 4-quinolinemethanol
derivative with a chemical structure related to that of qui-
nine. In healthy, non-pregnant human volunteers, peak
plasma concentrations of around 250 μg/L are observed
6–24 h following a single 250 mg oral administra-
tion[59]. Mefloquine has a mean elimination half-life of
2–4 weeks in healthy adults and is excreted in the bile fol-
lowing hepatic clearance from plasma. It can be detected
in low concentrations in human breast milk following a
single 250 mg dose[59]. In animal toxicity studies, meflo-
quine was teratogenic in mice and rats at a dose of 100
mg/kg/day and in rabbits at 80 mg/kg/day. At high doses
(160 mg/kg/day), mefloquine was also embryotoxic in
rabbits[59].
Mefloquine has been used alone for prophylaxis in the
pre-conception period and in all trimesters of preg-
nancy[4,37-39,41,60] and used for the treatment of chlo-
roquine and multidrug-resistant falciparum malaria in
pregnancy, both as monotherapy[4,61-63] and in combi-
nation with other antimalarials, particularly artemisinins
[64-66].
Mefloquine, at standard prophylactic doses of 250 mg/
week appears safe and effective when taken before con-
ception and during all trimesters of pregnancy[37,39,41].
In a prospective cohort of 236 pregnant travellers who
took a variety of prophylactic regimens, the risk of adverse
maternal and foetal outcomes among those exposed to
mefloquine in the first trimester was no greater than that
observed in women who took other antimalarials (chloro-
quine plus proguanil or sulphadoxine-pyrimethamine) or
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background population estimates[37]. Post-marketing
surveillance by Roche Pharmaceuticals based on 1,627
reports received between 1985 and 1996 found that the
risk of congenital abnormalities among women who took
mefloquine for prophylaxis either before conception or at
any point during pregnancy was around 4%, which was
no higher than reported background population rates of
around 2.5%[39]. Risk of miscarriage was unrelated to
time of first exposure. Mefloquine prophylaxis 250 mg/
week in the second and third trimester was also found to
be safe and effective in a randomized placebo-controlled
trial conducted among 339 women in Thailand[41]. Tran-
sient dizziness followed an initial 10 mg/kg loading dose,
but no serious maternal adverse events, spontaneous
abortions, stillbirths or neonatal deaths were reported.
However, an observational, non-comparative study
among seventy-two, female US soldiers stationed in
Somalia reported a risk of spontaneous abortion of 16.7%
(12/72) among women who took a standard dose meflo-
quine prophylaxis in the first trimester[60]. One molar
pregnancy was reported and 17 elective terminations car-
ried out. No developmental abnormalities were seen
among the 13 infants who were followed up for 1 year.
Given the context in which the study was conducted, the
small sample size and non-comparative study design, the
high rate of miscarriage reported should be interpreted
with caution.
There is good evidence that mefloquine is safe and effec-
tive in the treatment of falciparum malaria in pregnancy.
A low dose mefloquine treatment regimen (12.5 mg/kg as
single oral dose) given to 33 women in the second or third
trimester in Zaria, Nigeria was well tolerated, safe and
effective with no adverse maternal or foetal outcomes
reported[61]. In a large prospective study in Malawi,
4,187 women who presented to an antenatal clinic with
parasitaemia in the second or third trimester were ran-
domly assigned to 1 of 4 treatment and/or prophylaxis
regimens containing chloroquine or mefloquine[4].
Around 60% of women in all groups experienced minor
transient symptoms such as itching or dizziness but no
serious maternal adverse events were reported. The risk of
spontaneous abortion was 1.2% and that of stillbirth
3.9%. No neonatal deaths or congenital abnormalities
were reported and no group difference in adverse foetal
outcome was observed. Mefloquine in a total treatment
dose of 25 mg/kg was also safe and effective for the treat-
ment of chloroquine-resistant falciparum malaria in 40
women enrolled in the second or third trimester in a pro-
spective, non-comparative study conducted in Eastern
Sudan[63]. Minor adverse events only were reported (e.g.
18% experienced itching and 35% nausea).
In contrast, a retrospective study in Thailand reported a
borderline statistical association between mefloquine
treatment during the second and third trimester of preg-
nancy and excess odds of stillbirth compared to women
treated either with quinine or other antimalarials[62].
Among 208 women treated with 25 mg/kg mefloquine as
a single treatment dose during the second and third tri-
mester there was an excess of stillbirth (4.5%) compared
to 909 women treated either with quinine (1.6%) or other
antimalarials (1.4%). The stillbirth rate among women
who did not take antimalarials during their pregnancy (n
= 2470) was similar to that of the quinine group (1.8%).
There was no group difference in the odds of spontaneous
abortion or congenital abnormalities. Of the 61 stillbirths
that occurred, 38 could be verified in detail including all
nine cases associated with mefloquine exposure. Of these,
four stillbirths resulted from intrapartum complications
(prolonged labour, dystocia, eclampsia, cord prolapse),
three were associated with placenta praevia and two cases
were unclear ('accidental'; 'fever'). Among women
exposed to all other antimalarials, 3/5 cases were of
unknown cause as were 2/21 cases that occurred in
women who were not exposed to antimalarials during
pregnancy. After adjustment for confounders such as
maternal age, gravidity, malaria attack rates and trimester
of exposure, mefloquine was not significantly associated
with increased odds of stillbirth if taken in the three-
month prior to conception. In addition, the odds of still-
birth following mefloquine exposure in any trimester of
pregnancy was not significantly different to that associ-
ated with quinine. The retrospective design, ability to
trace only 72% (3,587/5,012) of women attending ante-
natal clinic in the observation period and biological
implausibility of the associations observed suggest that
these findings should be viewed within the context of
other reported research, particularly clinical trials of
mefloquine chemoprophylaxis, which indicate that
mefloquine is safe in pregnancy.
Several studies were identified which looked at the safety
and efficacy of mefloquine in combination with other
antimalarials. All were conducted among women in the
second or third trimester. A randomized, controlled trial
with 40 subjects in Nigeria compared artemether (3.2 mg/
kg intramuscularly once at entry) plus low dose meflo-
quine (7.5 mg/kg orally at 24, 48 h) versus artemether
alone (3.2 mg/kg at entry followed by 1.6 mg/kg/day for
4 days) for the treatment of multidrug-resistant falci-
parum malaria[64]. No serious adverse maternal or foetal
outcomes were reported. The artemether-mefloquine
combination was acceptable, safe and efficacious. In
another small study in Thailand, 60 women were enrolled
during the second or third trimester and treated with
artesunate (2 mg/kg once then 1 mg/kg twice daily for 5
days) plus mefloquine (15 mg/kg once then 10 mg/kg 6 h
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later) or quinine alone (10 mg/kg/day for 7 days)[67].
Fever and parasite clearance times were significantly
shorter in the artesunate-mefloquine group, and fewer
minor adverse events reported. No serious adverse events
were observed.
A randomized, open-label clinical trial among 108 second
and third trimester pregnant women in northwest Thai-
land compared a three-day mefloquine-artesunate regi-
men (MAS3; mefloquine 15 mg/kg on day 1; 10 mg/kg on
day 2 plus artesunate 4 mg/kg/day on days 0, 1, 2) versus
seven days treatment with quinine (Q7; 10 mg/kg three
times daily for 7 days) for multidrug-resistant falciparum
malaria[66]. A number of serious adverse events were
reported: one maternal death, unrelated to malaria (it is
not stated in which arm); two mid-trimester abortions
(both in the MAS3 arm vs. none in the Q7 arm); and five
neonatal deaths (three in the MAS3 arm vs. two in the Q7
arm). There were no stillbirths and no significant differ-
ences between arms in mean birthweight, proportion of
LBW infants or developmental milestones at 12 months.
Minor adverse events such as dizziness (87% vs. 45%; RR
1.93; 95% CI 1.14, 3.25) and tinnitus (66% vs. 17%; RR
3.93; 95% CI 1.98, 7.80) were more common in the Q7
than MAS3 group. MAS3 was more effective and better
tolerated than Q7, and was associated with significantly
reduced gametocyte carriage time (2.3 vs. 46.9/1000 per-
son weeks respectively; p < 0.001). PCR adjusted recrudes-
cence rates at 63 days were 33% in the Q7 group
compared to 2% in the MAS3 group (p = 0.001).
A phase III equivalence trial comparing intermittent SP
and mefloquine alone for the prevention of malaria-
related morbidity in pregnancy is currently underway in
Benin[44].
Azithromycin
Azithromycin is a macrolide antibiotic derived from
erythromycin which has an elimination half-life of 68 h in
healthy human volunteers and is excreted largely
unchanged in the bile following hepatic clearance[68]. In
pregnancy, the placenta appears to act as an effective bar-
rier to foetal exposure with limited placental transfer of
macrolide antibiotics observed following maternal
administration[69]. In a prospective study among 20
third trimester pregnant women, undertaken to assess
maternal and transplacental pharmacokinetics of azithro-
mycin, peak maternal serum azithromycin levels occurred
within 6 h of a single 1 g oral dose and declined rapidly
over the next 24 h[70]. Myometrial, adipose and placental
azithromycin levels were sustained for up to 72 h post
administration.
Azithromycin has been used extensively to treat sexually-
transmitted and other bacterial infections during preg-
nancy in total treatment doses of up to 1–2 g and is con-
sidered a safe alternative for the treatment of chlamydia,
mycoplasma and group B streptococci in pregnant
women who are allergic to beta-lactam antibiotics [71-
73].
Azithromycin is not yet licensed for use as an antimalarial
agent but has shown promising activity against P. falci-
parum in vitro[74,75], in the murine malaria model[76]
and in randomized controlled clinical trials [77-79]. A
phase III randomized placebo-controlled clinical trial of
azithromycin prophylaxis (750 mg loading dose followed
by 250 mg/day for 20 weeks) versus doxycycline (100 mg/
day for 20 weeks) conducted among 300 non-pregnant
Indonesian adults (286/300 male) found that azithromy-
cin was safe and well tolerated when used alone for the
prevention of falciparum malaria in Northeast Papua[77].
No serious adverse events were reported. One subject
developed an erythematous maculopapular rash that was
probably related to azithromycin exposure and which
necessitated withdrawal from the study. Prophylactic effi-
cacy was 72% which suggests that azithromycin should be
used in combination with other antimalarials rather than
used alone as a first-line agent for prevention. A clinical
trial among non-pregnant adults in Kenya reported simi-
lar levels of tolerability, safety and efficacy[78]. The effi-
cacy of azithromycin in combination with other
antimalarials for the treatment of uncomplicated falci-
parum malaria was assessed in a randomized controlled
trial among 202 non-pregnant adults in Thailand[79]. A
combination of artesunate 200 mg once followed by azi-
thromycin 500 mg daily for 3 days was more effective
than artesunate alone given daily for 3 days but was less
effective than an artesunate plus mefloquine regimen
given over 3 days. Cure rates at 28 days in the three groups
were 56%, 44% and 98% respectively. No serious adverse
events were reported in any of the treatment groups.
To date, no clinical trials have been conducted among
pregnant women but a phase III clinical trial of intermit-
tent SP plus azithromycin in pregnancy versus intermit-
tent SP alone is currently underway in Malawi[46].
Proguanil
The elimination half-life of proguanil is 12 – 21 h in
healthy adult volunteers and around 40–60% of the drug
is eliminated by urinary excretion. Proguanil is metabo-
lized by a cytochrome P450 isoenzyme to an active
metabolite (cycloguanil), responsible for antimalarial
activity[80]. Late pregnancy and use of oral contraceptives
impair formation of the active metabolite, probably due
to inhibition of the metabolizing isoenzyme as a result of
elevated oestrogen levels[80]. The pharmacokinetics of
proguanil and cycloguanil are significantly altered in preg-
nant women with malaria compared to healthy volun-
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teers and children with uncomplicated falciparum
malaria[81]
Proguanil has been used extensively for malaria chemo-
prophylaxis in travellers, including pregnant women and
children and is considered one of the safest antimalarials
currently available[37,42,58,82]. A randomized control-
led clinical trial in 200 antenatal clinic attenders carried
out in Nigeria concluded that proguanil given in a daily
dose of 100 mg daily was safe, well tolerated and effective
in all trimesters of pregnancy[42]. Taken alone or in com-
bination with chloroquine, proguanil chemoprophylaxis
was similarly well tolerated and effective in a randomized
prospective study among 327 antenatal clinic attenders in
Muheza, Tanzania[82] and in a prospective cohort of 236
first trimester pregnant travellers[37].
Proguanil-atovaquone
Proguanil has also been used in fixed combination with
atovaquone (100 mg/250 mg respectively) in the com-
mercially available preparation Malarone© (GlaxoSmithK-
line). Atovaquone has an elimination half life of 2–3 days
in adult volunteers and around 95% is excreted
unchanged in the bile[83]. A randomized double-blind
study compared mefloquine alone and proguanil-
atovaquone for chemoprophylaxis in 976 non-pregnant
travelers and found that both regimens were similarly
effective but that the proguanil-atovaquone combination
was better tolerated[84]. In an open-label randomized
controlled treatment trial among 182 non-pregnant
adults with multidrug-resistant falciparum malaria in
Thailand, proguanil-atovaquone was more effective and
better tolerated than mefloquine[85]. In a small safety
and efficacy study among 26 third trimester pregnant
women conducted in Thailand and Zambia, subjects pre-
senting with acute uncomplicated falciparum malaria
were given proguanil-atovaquone 100 mg/250 mg daily
for 3 days[81]. Median fever clearance time was 56 h in
Thailand and 52 h in Zambia; median parasite clearance
times were 51 h and 24 h respectively. The 28-day cure
rate was 100% at both sites. No serious maternal or foetal
adverse outcomes were reported. Minor adverse events
included headache, nausea and vomiting but occurred in
less than 10% and were probably due to the underlying
infection.
A randomized open-label clinical trial among 81 second
and third trimester pregnant women in Thailand com-
pared quinine and artesunate-atovaquone-proguanil
(AAP) for the treatment of uncomplicated falciparum
malaria and found that women treated with AAP had
shorter fever and parasite clearance times and lower treat-
ment failure rates (5% vs. 37%) compared to those in the
quinine group[86]. The AAP combination also appeared
safe and was well tolerated compared to quinine.
Chlorproguanil-dapsone
Chlorproguanil (Lapudrine®) has a similar mode of action
and pharmacokinetic profile to proguanil but has a
slightly longer elimination half-life (around 32 h)[80].
The drug has primarily been used in fixed dose co-formu-
lation with dapsone (diaminodiphenylsulfone), available
commercially as Lapdap© (GlaxoSmithKline). Despite evi-
dence from a number of clinical trials of the safety and
efficacy of this combination in the treatment of uncompli-
cated malaria in children[29,87,88] and pregnant
women[89], a recent WHO report[80] concluded that the
combination should continue to be used with caution,
particularly in areas where glucose-6-phosphate dehydro-
genase (G6PD) deficiency is common. Treatment trials of
chlorproguanil-dapsone in pregnancy are currently under-
way in Tanzania[90] and in Mali[91]. A combination of
chlorproguanil-dapsone plus artesunate (CDA) is also
under development[92] and a multicentre phase III clini-
cal trial comparing the efficacy and safety of CDA and
artemether-lumefantrine in the treatment of uncompli-
cated falciparum malaria in children and adolescents is
about to start in four countries in East and West
Africa[93].
Artemisinins
Artemisinin compounds (artemether, artesunate, dihy-
droartemisinin) are derived from sweet wormwood
(Artemisia annua), a herb which has been used in tradi-
tional Chinese medicine for over 2000 years[55,94]. All
are potent rapid-acting blood schizonticides with elimina-
tion half-lives from around 40 minutes to several
hours[51].
All artemisinin analogues are associated with embryotox-
icity over a narrow dose range in the rat and rabbit where
embryo-lethality, late resorption and morphological
abnormalities (such as abnormal development of the car-
diovascular system, axial skeleton and limbs) have been
reported[94,95]. There is also some evidence from animal
models that artemisinins given later in pregnancy have
adverse effects on foetal body weight and survival[95].
The mechanism of developmental toxicity in animals is
unclear. In rats, the yolk sac is highly susceptible to artem-
isinin compounds[96], but recent studies in monkeys,
which showed high rates of foetal loss, indicate that other
mechanisms must be involved in higher mammals[97].
Published data from clinical trials in humans is very lim-
ited. Data from a total of 864 women exposed to artemisi-
nin compounds during the second and third trimester of
pregnancy have been reported to date with no evidence of
drug-related adverse maternal or foetal out-
come[64,66,67,86,98-100]. Published data on safety in
the first trimester is limited to 50 women in The Gam-
bia[99] and 108 in Thailand[49,100] with similar find-
ings. None of the studies conducted to date have been
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specifically designed to capture excess early pregnancy
loss, the key adverse pregnancy outcome that might be
expected based on animal toxicity data.
Following two expert consultations in 2002, WHO recom-
mended that artemisinins should not be used in the first
trimester except in life-threatening situations where other
antimalarials were not suitable, should be used with cau-
tion in the second and third trimesters and that further
research be conducted to establish the pharmacokinetics
of artemisinins during pregnancy, mechanism of toxicity
and the relevance of animal toxicity data to humans[95].
Pharmacovigilance including post-exposure surveillance
and pregnancy registers were also recommended. The
pharmacokinetics of dihydroartemisinin following oral
artesunate treatment was recently described in 24 second
and third trimester pregnant women with uncomplicated
falciparum malaria in Thailand[101].
Artemether-lumefantrine
The only fixed-dose artemisinin combination therapy
(ACT) currently available is artemether-lumefantrine
(Coartem©/Riamet©), which is available at subsidized cost
to malaria-endemic countries following a special pricing
agreement established in 2001 between WHO and the
manufacturer, Novartis[52]. Artemether-lumefantrine is
now first-line treatment for uncomplicated falciparum
malaria in adults and children in 19 countries in sub-
Saharan Africa and 56 countries worldwide[52]. No treat-
ment or prevention trials in pregnancy have to date been
published.
Dihydroartemisinin-piperaquine
Dihydroartemisinin is a derivative of artemisinin and the
principal active metabolite of artesunate and artemether
with an elimination half-life of 40–60 minutes[51]. Piper-
aquine is a 4-aminoquinoline structurally related to chlo-
roquine, originally developed in China in the 1960's[102]
and has an elimination half-life of 3 to 4 weeks[51]. Fol-
lowing the widespread introduction of piperaquine as
monotherapy in China during the 1970's (including mass
prophylaxis programmes in some provinces), P. falci-
parum piperaquine-resistance emerged in the mid-1990's,
when efforts were then made to formulate the drug in var-
ious combinations e.g. with trimethoprim, primaquine
and others[103]. Dihydroartemisinin was selected as the
best partner and a fixed dose co-formulation dihyroartem-
isinin-piperaquine (DP; Artekin©/Eurartekin©) was devel-
oped through an international public-private partnership
between Holleykin Pharmaceutical, China; Sigma-Tau
Industries, Italy; the University of Oxford, UK; and the
Medicines for Malaria Venture (MMV)[104]. DP has been
used extensively in China, Viet Nam, Cambodia and other
parts of SE Asia and shown to be safe, effective and well
tolerated in the treatment of uncomplicated, multidrug-
resistant falciparum malaria in children and
adults[103,105-107]. Phase II/III clinical trials of DP for
intermittent preventive treatment in infants (IPTi) are
already underway in SE Asia and Africa[92] and the com-
bination may soon become more widely available once
international drug licensing and registration procedures
have been completed. To date however, no clinical trials
have been conducted among pregnant women.
Other artemisinin combination therapies
A variety of new ACTs are currently being evaluated in
phase II and III clinical trials in children and non-preg-
nant adults. Amodiaquine plus artesunate is being devel-
oped in fixed dose co-formulation as Coarsucam© (Sanofi-
Aventis). Clinical trials in Ghana[108] and Tanzania[109]
have reported encouraging results with this combination
in children under 5 years and a multicentre treatment trial
in adults and children is about to start in Cameroon,
Madagascar, Mali and Senegal.[110]. Given uncertainty
about the safety of amodiaquine in pregnancy[48,49], it is
unlikely that this combination will enter clinical IPTp tri-
als in the near future. The combination may, however, be
a promising candidate for evaluation in clinical trials for
IPTi, particularly in West Africa where amodiaquine-SP
has shown encouraging results [111-113].
The efficacy of dihydroartemisinin-mefloquine (DHA-
MQ) compared to DHA alone and chloroquine alone for
the treatment of uncomplicated falciparum malaria was
recently described in a small study among 75 children
aged 2–13 years conducted in Nigeria[114] but no pub-
lished data on the use of this combination in pregnancy,
evidence of clinical trials in progress or plans to develop a
fixed dose formulation were identified during this review.
Pyronaridine, a Mannich-base schizontocide structurally
related to the aminoacridine drug quinacrine, which
exerts its antimalarial action by forming complexes with
haematin[115], is being developed in fixed dose co-for-
mulation with artesunate (PANDA)[92]. A phase II clini-
cal trial is currently ongoing in children and adolescents
in Gabon[116]. Pyronaridine has also shown promising
activity in combination with dihydroartemisinin[117].
Chlorproguanil-dapsone-artesunate (CDA), artesunate-
atovaquone-proguanil (AAP) and artesunate-SP are other
promising ACTs under development, as described above.
Discussion
The pharmacokinetics, dosing regimen, efficacy and safety
profile of antimalarials currently used to treat and prevent
falciparum malaria in adults and children are well-
described. This is not the case in pregnancy where the lim-
ited data available in each of these areas makes it difficult
to predict which drugs are likely to be the best candidates
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for treating and preventing infection. Many antimalarials
are contra-indicated in pregnancy (e.g. primaquine, doxy-
cycline, halofantrine, tafenoquine), whilst the safety of
several promising candidates remains unclear[58]. In
malaria-endemic countries, where antenatal HIV preva-
lence is high, the increased risk of serious adverse events
associated with some antimalarials (e.g. severe skin reac-
tions with SP in women with co-infection[54]) and drug
interactions with anti-retrovirals used for the prevention
of mother to child HIV transmission (e.g. SP interacts with
nevirapine and zidovudine[118]) are also important fac-
tors to consider. Malaria in pregnancy is unique and char-
acterized by placental sequestration of P. falciparum-
infected erythrocytes following their adherence to placen-
tal chondroitin sulphate A (CSA)[119] and hyaluronic
acid[120], which essentially allows the placenta to act as a
'privileged site' for parasite replication[36]. Pregnant
women in all transmission areas have an increased sus-
ceptibility to malaria and other infections due to changes
in cellular mediated immune responses [121-123], which
persist into the postpartum period[6,8]. Physiological
changes such as increased intravascular volume, delayed
gastric emptying time, elevated oestrogen and cortisol lev-
els and increased body fat content alter the absorption,
distribution and elimination of many antimalarials dur-
ing pregnancy[81]. For example the pharmacokinetics of
atovaquone, proguanil, cycloguanil and dihydroartem-
isnin are significantly altered in pregnant women with
malaria compared to healthy volunteers or adults and
children with malaria[81,101]. For candidate IPTp combi-
nations there is the added complication that there is still
some debate as to how IPTp actually works: repeated short
courses of antimalarials may act mainly by intermittent
suppressive chemotherapy ('prophylactic effect'); by inter-
mittent treatment of repeated infections ('treatment
effect'); or by some combination of these effects[36,55].
Similar issues are also being debated about IPTi [124].
Given the early success of SP-IPTp in high transmission
areas, the slow parasite clearance times and long elimina-
tion half-lives of each of the component drugs[125], it
seems likely that the 'prophylactic effect' is the predomi-
nant mode of action, at least in this combination.
How then to decide which antimalarials are likely to be
effective for IPT in pregnancy and which combinations
should be prioritized for investigation in clinical trials
(Table 1)? If the effect of IPTp is mainly prophylactic, then
short-acting drugs such as quinine and the artemesinins
would be expected to provide little direct benefit in
asymptomatic pregnant women living in high-transmis-
sion areas since rapid parasite elimination is unnecessary.
Drugs with long half-lives such as mefloquine, piper-
aquine or lumefantrine would, therefore, appear better
choices, but monotherapy with any of these agents would
be inappropriate given global patterns of drug resistance
and the consensus on the need for combination therapies
[51-54]. There is some evidence that combining short-act-
ing artemisinins with longer-acting agents is likely to
delay the emergence of resistance to the slowly-eliminated
component[51,53,55]. Conversely, some authors advise
combining drugs with similar elimination half-lives due
to the risk of resistance emerging to the longer-acting drug
because of it's persistence alone at sub-therapeutic levels
once the rapidly eliminated drug has been excreted[54].
Combining drugs that have different molecular targets is
also preferable to reduce the risk of resistance[51,54].
Acceptability, cost, possibility of a fixed-dose formula-
tion, and a simple dosing regimen are other important
considerations[53].
Based on these criteria, dihydroartemisinin-piperaquine
appears an appropriate candidate for IPTp and should be
considered for phase II/III clinical trials in second and
third trimester pregnant women. The combination is rela-
tively inexpensive (around US$ 1.00 for an adult treat-
ment course, which is comparable to Coartem©)[126];
combines a very short acting artemisinin with a longer act-
ing partner with a different mode of action; and is availa-
ble in fixed-dose co-formulation. Dihydroartemisinin is
the active metabolite of many artemisinin compounds,
which appear to be effective, well tolerated and safe after
the first trimester; the evidence for the safety of piper-
aquine is, however, less clear, indicating the need for pre-
liminary phase II studies.
Artemether-lumefantrine may also be a suitable candi-
date: a relatively inexpensive, fixed co-formulation is
available and the partner drugs have different molecular
targets. The 'prophylactic effect' conferred by lumefantrine
may not be sufficient however, given its relatively short
half-life compared to sulphadoxine, pyrimethamine,
mefloquine or piperaquine.
Mefloquine in combination with artemether or artesunate
has the advantage of a similar elimination profile to dihy-
droartemisnin-piperaquine and the safety of such combi-
nations in the treatment of pregnancy-associated malaria
is reasonably well-established. Indeed, the extensive data
available on mefloquine use in pregnancy compared to
piperaquine suggest that dihydroartemisinin-mefloquine
could enter phase III trials ahead of dihydroartemisinin-
piperaquine. Cost and the lack of fixed dose co-formula-
tions (although these are currently under development)
are disadvantages. Combining mefloquine with the rela-
tively long acting azithromycin is another option and
likely to have additional health benefits by reducing
maternal and perinatal infections, which may offset cost
concerns. Sexually-transmitted infections (STIs) are com-
mon in women of childbearing age in Africa and may go
undiagnosed and untreated during pregnancy[127].
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Table 1: Pharmacology of selected candidates for IPTp
Drug Mode of action Elimination half life Advantages/disadvantages
Artemether Inhibits falciparum sarcoplasmic-
endoplasmic reticulum calcium 
ATPase
3 – 7 h (converted to DHA) Appears safe in the second and third trimester
Widely available in a cheap, fixed dose co-
formulation with lumefantrine (Coartem©/
Riamet©)
Artemisinin Inhibits falciparum sarcoplasmic-
endoplasmic reticulum calcium 
ATPase
2 – 3 h (converted to DHA) Appears safe in the second and third trimester
Fixed dose co-formulations unavailable
Artesunate Inhibits falciparum sarcoplasmic-
endoplasmic reticulum calcium 
ATPase
2 – 5 mins (converted to DHA) Appears safe in the second and third trimester
Fixed dose co-formulations unavailable
Atovaquone Selective inhibitor of parasite 
mitochondrial metabolism
48 – 72 h Appears safe in the third trimester
Available only in fixed dose co-formulation with 
proguanil (Malarone©), which is expensive 
outside specific donation programmes
Azithromycin Exact mode of action unknown 68 h Safe in all trimesters where has been used 
extensively in STI treatment
Expensive; fixed dose co-formulations 
unavailable
Chlorproguanil Folic acid antagonist (inhibits 
dihydrofolate reductase)
32 h Cheap; appears safe in the third trimester and 
likely to be safe earlier in pregnancy based on 
experience with proguanil
Available only in fixed dose co-formulation with 
dapsone (Lapdap©), which WHO have 
recommended be used with caution in areas of 
high G6PD deficiency
Dapsone Folic acid antagonist (inhibits 
dihydropteroate synthase)
31 h Cheap; appears safe in the third trimester
Available in fixed dose co-formulation with 
chlorproguanil (Lapdap©), which WHO have 
recommended be used with caution in areas of 
high G6PD deficiency
Dihydroartemisinin 
(DHA)
Inhibits falciparum sarcoplasmic-
endoplasmic reticulum calcium 
ATPase
40 – 60 mins Likely to be safe in the second and third 
trimester
Available in SE Asia, China in a cheap fixed dose 
co-formulation with piperaquine (Artekin©/
Eurartekin©)
Lumefantrine Inhibits metabolism of haem within 
parasite acid food vacuole
4 – 6 days Safety in children and adults established but no 
data available in pregnancy
Widely available in a cheap [through WHO 
pricing agreement], fixed dose co-formulation 
with artemether (Coartem©/Riamet©)
Mefloquine Exact mode of action unknown 2 – 4 weeks Appears safe in the second and third trimester
Expensive; fixed dose co-formulations 
unavailable
Piperaquine Inhibits detoxification of haem 3 – 4 weeks Safety in children and adults established but no 
data available in pregnancy
Available in SE Asia, China in a cheap, fixed dose 
co-formulation with dihydroartemisinin 
(Artekin©/Eurartekin©)
Proguanil Folic acid antagonist (inhibits 
dihydrofolate reductase)
12 – 21 h Cheap; appears safe in all trimesters
Available alone or in fixed dose co-formulation 
with atovaquone (Malarone©), which is 
expensive outside specific donation 
programmes
Pyrimethamine Folic acid antagonist (inhibits 
dihydrofolate reductase)
100 h Cheap; widely available in fixed-dose 
combination with sulphadoxine
Increasing resistance particularly in East Africa
Sulphadoxine Folic acid antagonist (inhibits 
dihydropteroate synthase)
200 h Cheap; widely available in fixed-dose 
combination with pyrimethamine
Increasing resistance particularly in East Africa
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Monthly azithromycin reduces STI incidence significantly
in high-risk groups[128] and is safe and effective for treat-
ing gonorrhoea as well as chlamydia infection during
pregnancy[71], which is associated with increased risk of
stillbirth, prematurity and LBW[129]. Mefloquine-azi-
thromycin may, therefore, represent a promising, safe and
effective combination for IPTp and should be considered
urgently for evaluation in phase III clinical trials.
Patterns of SP resistance vary across sub-Saharan Africa so
that new artemisinin-containing combinations with SP
may be appropriate in West Africa, given that these would
fulfil many of the criteria above. Such combinations are,
however, unlikely to succeed in East and Southern Africa,
given prevailing levels of resistance.
Are different types of drug combination needed in differ-
ent areas of malaria transmission? Evidence for the effec-
tiveness of IPTp comes primarily from studies conducted
in areas of intense perennial transmission (stable
malaria), but there may be a case for evaluating IPTp in
areas of low transmission (unstable malaria). The World
Health Organization recommends that IPTp be an inte-
gral part of national malaria control programmes in high/
medium perennial or seasonal transmission areas but cau-
tion that there is insufficient evidence for introducing
IPTp in low transmission settings where the principal
focus should be on effective case management and insec-
ticide-treated bednets[17]. In areas of highly seasonal
transmission there is some evidence to suggest that IPT
given only during periods of high transmission may be
effective, at least in infants[112], but no studies to date
have been reported from low transmission settings such as
South America or Asia, where the burden of pregnancy-
associated malaria is significant, but quite different from
that observed in areas of stable malaria and where the
contribution of Plasmodium vivax infection also needs to
be taken into consideration[36]. In addition, combina-
tions found to be efficacious in sub-Saharan Africa may be
of limited benefit in Asia due to their inability to prevent
relapse in P. vivax infection[130,131].
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